PARIS, November 21 /PRNewswire/ -- The first melatonergic antidepressant - Valdoxan(R)/Thymanax(R) (agomelatine) - has received a positive opinion from the European Medicines Agency's (EMEA) Committee for Medicinal Products for Human Use (CHMP) for its use in the treatment of adult patients with major depressive disorder (MDD).

Upon approval by the European Commission in early 2009, Valdoxan is expected to be marketed by Servier in European countries in the following months.

AMSTERDAM, Netherlands, November 21 /PRNewswire/ --

- AVG Replies to Announcement of Competitor's Replication of Its Anti- Virus Software Offering

AVG, a global anti-virus and Internet security software provider with over 85 million users in 167 countries, today responded to Microsoft's announcement of a free anti-virus software product slated to appear in mid-2009.

AVG, which for eight years has offered free anti-virus software to users worldwide, noted the multiple challenges Microsoft faces in supporting a free anti-virus software product -- chief among them the enormous overhead costs it will incur for customer service and support issues, as well as for ongoing product management and upgrades.

LONDON, November 21 /PRNewswire/ -- ICIS Heren, the market leading reporter on the European gas market has collaborated with C1 Energy Ltd, widely acknowledged as the leading information source on the Chinese oil and gas market. They have created a NEW fortnightly report with all the latest news which provides gas traders, suppliers, consultants and many more with all the information they need about China's gas market.

China Gas Markets fortnightly report provides: - Comprehensive, valuable and independent coverage of China's domestic gas markets, including LNG imports - Price assessments in Yuan - In-depth commentary and analysis of the latest trends and outlook

THOUSAND OAKS, California, November 21 /PRNewswire/ --

- First and Only Approved Platelet Producer Represents New Treatment Approach for Serious Chronic Autoimmune Disorder

Amgen (Nasdaq: AMGN) today announced that the European Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion recommending marketing authorisation for Nplate(TM) (romiplostim) in the European Union (EU). The CHMP recommends Nplate for adult chronic immune (idiopathic) thrombocytopenia purpura (ITP) splenectomised patients who are refractory to other treatments (e.g. corticosteroids, immunoglobulins). Nplate may be considered as second line treatment for adult non-splenectomised patients where surgery is contra-indicated.

Journalists and other readers should disregard the news release UsportStar.com Flies out of Development Phase, issued earlier today. The release was transmitted prematurely by PR Newswire.

For further information: Dreamscape Media Ltd, Mr Sameer Mitter, 8 The Courtyard, Buntsford Drive, Bromsgrove, Worcestershire, B60 3DJ, Tel: +44(0)1527-889278, Email: media@dsmstar.com . Press contact: Jay Jones, Logo Design Marketing, +44(0)1752830000, jay@logodesign.co.uk .

LONDON, November 21 /PRNewswire/ --

Quality leader Fronius International GmbH has been awarded the Frost Sullivan 2008 Best Practices Award for its development of the innovative and high performance Fronius IG Plus PV inverter series as well as for its outstanding service. With the development of this new product series, Fronius is setting new standards in the international inverter market.

(Logo: http://www.newscom.com/cgi-bin/prnh/20081117/FSLOGO)

The Frost Sullivan Award for Product Quality Leadership is bestowed upon the company that has demonstrated superior quality control over its competitors in product manufacturing. Quality control is an essential element of satisfying customers, increasing buying behavior, and assuring long-term market survival.

BAAR, Switzerland, November 21 /PRNewswire/ -- Manas Petroleum Corporation announces that the Board of Directors has unanimously appointed Dr. Richard Schenz as an Independent Director.

We are pleased to welcome Dr. Richard Schenz as a member of Manas' board, stated Heinz J. Scholz, Manas's Chairman of the Board. With his experience and expertise as the former CEO of OMV, Central Europe's leading oil and gas company, we see him becoming a valuable contributor to Manas's future.

Dr. Schenz studied technical physics in Vienna and finished with a PhD. In 1969 he started his career with the Austrian oil gas company OMV, and was its CEO from 1992 to 2001.

LONDON, November 21 /PRNewswire/ -- The average Great British mother can expect less than an hour and a half each day to themselves according to leading Child Trust Fund provider, The Children's Mutual (http://www.thechildrensmutual.co.uk/).

The average full-time working mum is even worse off with less than an hour a day of 'me time' - which is defined as quality time spent awake, without worrying about the stresses and strains of the daily grind! Unsurprisingly, nearly three quarters of these women felt that this was insufficient.

LONDON, November 21 /PRNewswire/ -- In a landmark test case in the High Court, Unite the union, has successfully defended the rights of vulnerable asbestos victims from insurers' attempts to avoid their liabilities.

The trade union has resisted a legal challenge by insurance companies which, if successful, could have deprived thousands of mesothelioma sufferers and their families of compensation.

The High Court today (November 21, 2008) ruled that Employers' Liability insurers remain liable to pay compensation for mesothelioma caused by exposure to asbestos in the work place if they insured the employer at the time the asbestos exposure occurred.